STOCK TITAN

Ultragenyx (RARE) legal chief sells 1,899 company shares in open market

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. executive Karah Herdman Parschauer reported an open-market sale of 1,899 shares of common stock at $24.62 per share. After this transaction, she directly holds 94,462 shares. Her holdings include 646 shares acquired under the company’s Employee Stock Purchase Plan and previously reported RSU-based common stock that remains subject to vesting conditions.

Positive

  • None.

Negative

  • None.
Insider Parschauer Karah Herdman
Role EVP and Chief Legal Officer
Sold 1,899 shs ($47K)
Type Security Shares Price Value
Sale Common Stock 1,899 $24.62 $47K
Holdings After Transaction: Common Stock — 94,462 shares (Direct)
Footnotes (1)
  1. Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Shares sold 1,899 shares Open-market sale on 2026-06-15
Sale price $24.62 per share Open-market transaction
Shares held after transaction 94,462 shares Direct ownership following sale
ESPP shares included 646 shares Acquired under Employee Stock Purchase Plan on 2026-04-30
open-market sale financial
"reported an open-market sale of 1,899 shares of common stock at $24.62"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Employee Stock Purchase Plan financial
"Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
RSUs financial
"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vesting conditions financial
"underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions"
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Ultragenyx (RARE) report for Karah Herdman Parschauer?

Ultragenyx reported that EVP and Chief Legal Officer Karah Herdman Parschauer sold 1,899 shares of common stock in an open-market transaction. This Form 4 filing details the sale and her updated share ownership position after the transaction.

At what price did the Ultragenyx (RARE) executive sell shares in this Form 4?

The Ultragenyx executive’s 1,899-share sale was executed at $24.62 per share. This recorded price reflects the open-market transaction reported, providing investors with transparency into the trade terms disclosed in the Form 4 filing.

How many Ultragenyx (RARE) shares does Karah Herdman Parschauer hold after the sale?

After the reported sale, Karah Herdman Parschauer directly holds 94,462 Ultragenyx common shares. This figure includes stock acquired through the company’s plans and awards, offering a clearer picture of her ongoing equity stake following the transaction.

What role does the insider hold at Ultragenyx (RARE) in this Form 4 filing?

The reporting person, Karah Herdman Parschauer, serves as Ultragenyx’s EVP and Chief Legal Officer. Her position as a senior officer makes her equity transactions subject to Form 4 reporting and public disclosure for investor awareness.

Does the Ultragenyx (RARE) Form 4 mention shares from an Employee Stock Purchase Plan?

Yes. The filing notes that her holdings include 646 shares acquired under Ultragenyx’s Amended and Restated Employee Stock Purchase Plan on April 30, 2026. This clarifies that part of her position comes from ongoing employee share purchase participation.

Are RSUs referenced in the Ultragenyx (RARE) Form 4 for this insider?

The Form 4 states that her reported holdings include shares of common stock underlying previously granted RSUs. These restricted stock units are subject to vesting conditions, meaning some equity exposure is tied to future service or performance requirements.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parschauer Karah Herdman

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP and Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026S1,899D$24.6294,462(1)(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026
2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
/s/ Karah Parschauer06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)